Aldeyra Therapeutics is delisting from Nasdaq due to failure to meet listing standards, impacting its future and the pharmaceutical sector.
| Name | Aldeyra Therapeutics, Inc. |
|---|---|
| CIK | 0001341235 |
| Tickers | ALDX |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 000000000 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 781-761-4904 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Aldeyra Therapeutics is delisting from Nasdaq due to failure to meet listing standards, impacting its future and the pharmaceutical sector.
Aldeyra Therapeutics reveals AQR Capital Management holds 1.11% of its common stock, indicating ongoing institutional interest in the pharmaceutical sector.
Aldeyra Therapeutics has filed an 8-K report detailing a recent event that may impact its operations and the pharmaceutical preparations industry.
Barclays PLC has acquired a 5.48% stake in Aldeyra Therapeutics, signaling confidence in the pharmaceutical preparations company.
Aldeyra Therapeutics, Inc. files Q3 2026 report, revealing key financial insights and operational updates in the pharmaceutical preparations sector.
654 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-17 | 8-K | 8-K | 3.01 | 0001193125-26-465667 | 001-36332 | 261566995 | 34 | 173410 | 1 | 1 |
| 2026-11-16 | 4 | 4 | 0001193125-26-463942 | 4667 | ||||||
| 2026-11-13 | 4 | 4 | 0001193125-26-460801 | 4730 | ||||||
| 2026-11-13 | 4 | 4 | 0001193125-26-460743 | 5328 | ||||||
| 2026-11-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001167557-26-000229 | 005-88182 | 261544827 | 34 | 9108 | |||
| 2026-11-09 | 8-K | 8-K | 8.01 | 0001193125-26-453537 | 001-36332 | 261535796 | 34 | 175915 | 1 | 1 |
| 2026-11-06 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000312069-26-000249 | 005-88182 | 261531256 | 34 | 6363 | |||
| 2026-11-05 | 10-Q | 10-Q | 0001193125-26-449742 | 001-36332 | 261527080 | 34 | 7705526 | 1 | 1 | |
| 2026-09-29 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-26-405954 | 001-36332 | 261419109 | 34 | 8223803 | 1 | 1 |
| 2026-08-12 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001167557-26-000132 | 005-88182 | 261265886 | 34 | 8952 | |||
| 2026-08-06 | 10-Q | 10-Q | 0001341235-26-000010 | 001-36332 | 261248731 | 34 | 7250198 | 1 | 1 | |
| 2026-07-30 | 8-K | 8-K | 1.01,9.01 | 0001193125-26-326337 | 001-36332 | 261224376 | 34 | 20078775 | 1 | 1 |
| 2026-07-27 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0002012383-26-002166 | 005-88182 | 261206037 | 34 | 10981 | |||
| 2026-07-15 | 8-K | 8-K | 8.01 | 0001193125-26-304880 | 001-36332 | 261177866 | 34 | 164138 | 1 | 1 |
| 2026-06-11 | 4 | 4 | 0001193125-26-267634 | 7956 | ||||||
| 2026-06-11 | 4 | 4 | 0001193125-26-267629 | 10382 | ||||||
| 2026-06-11 | 4 | 4 | 0001193125-26-267623 | 10301 | ||||||
| 2026-06-11 | 4 | 4 | 0001193125-26-267611 | 7970 | ||||||
| 2026-06-11 | 4 | 4 | 0001193125-26-267605 | 7929 | ||||||
| 2026-06-11 | 4 | 4 | 0001193125-26-267600 | 10236 | ||||||
| 2026-06-11 | 4 | 4 | 0001193125-26-267587 | 7835 | ||||||
| 2026-06-11 | 3 | 3 | 0001193125-26-267553 | 3267 | ||||||
| 2026-06-10 | 8-K | 8-K | 5.02,5.07,7.01,9.01 | 0001193125-26-264514 | 001-36332 | 261077711 | 34 | 275650 | 1 | 1 |
| 2026-06-05 | 4 | 4 | 0001193125-26-259637 | 5263 | ||||||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001193125-26-226558 | 005-88182 | 26986544 | 34 | 10342 | |||
| 2026-05-07 | 10-Q | 10-Q | 0001341235-26-000006 | 001-36332 | 26952973 | 34 | 7118049 | 1 | 1 | |
| 2026-05-01 | 8-K | 8-K | 7.01,9.01 | 0001193125-26-199157 | 001-36332 | 26928960 | 34 | 15690233 | 1 | 1 |
| 2026-04-27 | ARS | ARS | 0001193125-26-182133 | 001-36332 | 26901280 | 34 | 1022283 | |||
| 2026-04-27 | DEFA14A | DEFA14A | 0001193125-26-182118 | 001-36332 | 26901170 | 34 | 949433 | |||
| 2026-04-27 | DEF 14A | DEF 14A | 0001193125-26-182099 | 001-36332 | 26900990 | 34 | 2818026 | 1 | 1 | |
| 2026-04-20 | 8-K | 8-K | 5.02 | 0001193125-26-164198 | 001-36332 | 26875808 | 34 | 165808 | 1 | 1 |
| 2026-04-01 | 8-K | 8-K | 8.01 | 0001193125-26-137984 | 001-36332 | 26828618 | 34 | 165008 | 1 | 1 |
| 2026-03-31 | 4 | 4 | 0001193125-26-134631 | 8206 | ||||||
| 2026-03-26 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000102909-26-000589 | 005-88182 | 26797581 | 34 | 7386 | |||
| 2026-03-20 | 4 | 4 | 0001193125-26-117675 | 4712 | ||||||
| 2026-03-19 | 4 | 4 | 0001193125-26-116247 | 4669 | ||||||
| 2026-03-17 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-26-109511 | 001-36332 | 26759221 | 34 | 223756 | 1 | 1 |
| 2026-02-27 | S-8 | S-8 | 0001193125-26-083135 | 333-293882 | 26701589 | 33 | 207413 | 1 | 1 | |
| 2026-02-27 | 10-K | 10-K | 0001193125-26-083012 | 001-36332 | 26701082 | 34 | 11993980 | 1 | 1 | |
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001193125-26-054525 | 005-88182 | 26640556 | 34 | 10936 | |||
| 2025-12-31 | 8-K | 8-K | 5.02 | 0001193125-25-338394 | 001-36332 | 251617928 | 34 | 137321 | 1 | 1 |
| 2025-12-16 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-25-319638 | 001-36332 | 251573017 | 34 | 212966 | 1 | 1 |
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001193125-25-282830 | 005-88182 | 251485387 | 34 | 10937 | |||
| 2025-11-13 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-25-278804 | 001-36332 | 251475328 | 34 | 14927578 | 1 | 1 |
| 2025-11-05 | 10-Q | 10-Q | 0001193125-25-266989 | 001-36332 | 251454252 | 34 | 8156312 | 1 | 1 | |
| 2025-10-28 | 8-K | 8-K | 8.01,9.01 | 0001193125-25-252200 | 001-36332 | 251421241 | 34 | 486798 | 1 | 1 |
| 2025-08-19 | 8-K | 8-K | 9.01 | 0000950170-25-109932 | 001-36332 | 251229624 | 34 | 275635 | 1 | 1 |
| 2025-08-15 | 4 | 4 | 0000950170-25-109391 | 4662 | ||||||
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000950170-25-108920 | 005-88182 | 251219618 | 34 | 10832 | |||
| 2025-08-13 | 4 | 4 | 0000950170-25-108210 | 5555 | ||||||
| 2025-08-12 | 144 | xsl144X01/primary_doc.xml | 0001836354-25-000003 | 001-36332 | 251208242 | 33 | 4448 | |||
| 2025-08-07 | 10-Q | 10-Q | 0000950170-25-104971 | 001-36332 | 251193803 | 34 | 8370043 | 1 | 1 | |
| 2025-07-17 | 8-K | CURRENT REPORT | 8.01,9.01 | 0001213900-25-064869 | 001-36332 | 251128797 | 34 | 217203 | 1 | 1 |
| 2025-06-26 | 8-K | CURRENT REPORT | 7.01,8.01,9.01 | 0001213900-25-058035 | 001-36332 | 251075035 | 34 | 232427 | 1 | 1 |
| 2025-06-17 | 8-K | FORM 8-K | 8.01,9.01 | 0001213900-25-054949 | 001-36332 | 251051805 | 34 | 218991 | 1 | 1 |
| 2025-06-12 | 4 | 4 | 0000950170-25-085489 | 7761 | ||||||
| 2025-06-12 | 4 | 4 | 0000950170-25-085475 | 7821 | ||||||
| 2025-06-12 | 4 | 4 | 0000950170-25-085454 | 10102 | ||||||
| 2025-06-12 | 4 | 4 | 0000950170-25-085445 | 10101 | ||||||
| 2025-06-12 | 4 | 4 | 0000950170-25-085441 | 10248 | ||||||
| 2025-06-12 | 4 | 4 | 0000950170-25-085419 | 10167 | ||||||
| 2025-06-11 | 8-K | 8-K | 5.07 | 0000950170-25-084820 | 001-36332 | 251039876 | 34 | 205884 | 1 | 1 |
| 2025-05-14 | 10-Q | 10-Q | 0000950170-25-071602 | 001-36332 | 25947046 | 34 | 8056075 | 1 | 1 | |
| 2025-05-06 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-25-113275 | 001-36332 | 25915177 | 34 | 1898202 | 1 | 1 |
| 2025-04-25 | ARS | ARS | 0001193125-25-096939 | 001-36332 | 25874554 | 34 | 10917119 | |||
| 2025-04-25 | DEFA14A | DEFA14A | 0001193125-25-096925 | 001-36332 | 25874507 | 34 | 713323 | |||
| 2025-04-25 | DEF 14A | DEF 14A | 0001193125-25-096899 | 001-36332 | 25874384 | 34 | 2911499 | 1 | 1 | |
| 2025-04-18 | 4 | 4 | 0000950170-25-055900 | 5381 | ||||||
| 2025-04-18 | 3 | 3 | 0000950170-25-055877 | 3126 | ||||||
| 2025-04-17 | 8-K | CURRENT REPORT | 5.02,9.01 | 0001213900-25-032947 | 001-36332 | 25847189 | 34 | 234945 | 1 | 1 |
| 2025-04-07 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000950170-25-051722 | 005-88182 | 25819310 | 34 | 10909 | |||
| 2025-04-07 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-25-007163 | 9412 | ||||||
| 2025-04-03 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-25-072424 | 001-36332 | 25810380 | 34 | 5512251 | 1 | 1 |
| 2025-03-28 | 10-K/A | 10-K/A | 0000950170-25-046946 | 001-36332 | 25787777 | 34 | 300817 | 1 | 1 | |
| 2025-03-06 | 4 | 4 | 0000950170-25-034674 | 5453 | ||||||
| 2025-03-06 | 4 | 4 | 0000950170-25-034648 | 5452 | ||||||
| 2025-02-28 | S-8 | S-8 | 0001193125-25-042772 | 333-285460 | 25691910 | 33 | 83772 | |||
| 2025-02-28 | 10-K | 10-K | 0000950170-25-030102 | 001-36332 | 25691076 | 34 | 13430322 | 1 | 1 | |
| 2024-11-18 | 8-K | CURRENT REPORT | 1.01,8.01,9.01 | 0001213900-24-099333 | 001-36332 | 241469739 | 34 | 238915 | 1 | 1 |
| 2024-11-14 | SC 13G/A | SC 13G/A | 0001193125-24-258735 | 005-88182 | 241463739 | 34 | 60202 | |||
| 2024-11-07 | 10-Q | 10-Q | 0000950170-24-123248 | 001-36332 | 241435402 | 34 | 7489439 | 1 | 1 | |
| 2024-10-21 | 4 | 4 | 0000950170-24-116048 | 6315 | ||||||
| 2024-10-03 | 8-K | CURRENT REPORT | 8.01,9.01 | 0001213900-24-084844 | 001-36332 | 241349884 | 34 | 228401 | 1 | 1 |
| 2024-10-02 | 8-K | 8-K | 1.01,2.03,9.01 | 0001193125-24-231158 | 001-36332 | 241347403 | 34 | 196054 | 1 | 1 |
| 2024-09-10 | 3 | 3 | 0000950170-24-105145 | 3204 | ||||||
| 2024-09-03 | 8-K | 8-K | 5.02 | 0001193125-24-211645 | 001-36332 | 241272303 | 34 | 149156 | 1 | 1 |
| 2024-08-14 | 4 | 4 | 0000950170-24-097071 | 5419 | ||||||
| 2024-08-14 | 4 | 4 | 0000950170-24-097070 | 5665 | ||||||
| 2024-08-12 | 144 | xsl144X01/primary_doc.xml | 0001928391-24-000002 | 001-36332 | 241198160 | 33 | 4520 | |||
| 2024-08-12 | 144 | xsl144X01/primary_doc.xml | 0001928391-24-000001 | 001-36332 | 241198119 | 33 | 4491 | |||
| 2024-08-08 | 8-K | CURRENT REPORT | 7.01,8.01,9.01 | 0001213900-24-066327 | 001-36332 | 241185984 | 34 | 3688347 | 1 | 1 |
| 2024-08-01 | 424B5 | 424B5 | 0001193125-24-191601 | 333-277753 | 241167663 | 33 | 400236 | |||
| 2024-08-01 | 8-K | 8-K | 1.01,9.01 | 0001193125-24-191518 | 001-36332 | 241166774 | 34 | 453958 | 1 | 1 |
| 2024-08-01 | 10-Q | 10-Q | 0000950170-24-089238 | 001-36332 | 241166475 | 34 | 8789928 | 1 | 1 | |
| 2024-06-20 | 8-K | CURRENT REPORT | 8.01,9.01 | 0001213900-24-054003 | 001-36332 | 241054030 | 34 | 4799407 | 1 | 1 |
| 2024-06-13 | 8-K | CURRENT REPORT | 7.01,9.01 | 0001213900-24-052234 | 001-36332 | 241039998 | 34 | 219528 | 1 | 1 |
| 2024-06-07 | 8-K | 8-K | 5.07 | 0001193125-24-157328 | 001-36332 | 241029379 | 34 | 154204 | 1 | 1 |
| 2024-06-06 | 4 | 4 | 0000950170-24-069900 | 10252 | ||||||
| 2024-06-06 | 4 | 4 | 0000950170-24-069890 | 10105 | ||||||
| 2024-06-06 | 4 | 4 | 0000950170-24-069888 | 7766 | ||||||
| 2024-06-06 | 4 | 4 | 0000950170-24-069887 | 7826 | ||||||
| 2024-06-06 | 4 | 4 | 0000950170-24-069885 | 10106 | ||||||
| 2024-06-06 | 4 | 4 | 0000950170-24-069874 | 10171 | ||||||
| 2024-05-02 | 10-Q | 10-Q | 0000950170-24-052056 | 001-36332 | 24908053 | 34 | 6433735 | 1 | 1 | |
| 2024-04-25 | 8-K | CURRENT REPORT | 7.01,8.01,9.01 | 0001213900-24-035953 | 001-36332 | 24872839 | 34 | 20926006 | 1 | 1 |
| 2024-04-24 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2024-04-24 16:00:00 | 9999999995-24-001104 | 333-277753 | 24872631 | 33 | 1965 | ||
| 2024-04-22 | CORRESP | filename1.htm | 0001193125-24-104917 | 7317 | ||||||
| 2024-04-22 | ARS | ARS | 0001193125-24-104887 | 001-36332 | 24861416 | 34 | 1086949 | |||
| 2024-04-22 | DEFA14A | DEFA14A | 0001193125-24-104866 | 001-36332 | 24861346 | 34 | 787246 | |||
| 2024-04-22 | DEF 14A | DEF 14A | 0001193125-24-104862 | 001-36332 | 24861327 | 34 | 1053775 | |||
| 2024-04-17 | 4/A | 4/A | 0000950170-24-045113 | 6010 | ||||||
| 2024-04-17 | 4/A | 4/A | 0000950170-24-045108 | 6118 | ||||||
| 2024-04-08 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-24-008171 | 11362 | ||||||
| 2024-04-03 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-24-007959 | 13348 | ||||||
| 2024-03-28 | 8-K | CURRENT REPORT | 7.01,9.01 | 0001213900-24-026871 | 001-36332 | 24793445 | 34 | 233900 | 1 | 1 |
| 2024-03-13 | UPLOAD | filename1.pdf | 0000000000-24-002751 | 333-277753 | 40512 | |||||
| 2024-03-12 | 4 | 4 | 0000950170-24-030314 | 7748 | ||||||
| 2024-03-12 | 4 | 4 | 0000950170-24-030311 | 10766 | ||||||
| 2024-03-12 | 4 | 4 | 0000950170-24-030309 | 9549 | ||||||
| 2024-03-12 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-002180 | 001-36332 | 24742026 | 33 | 9223 | |||
| 2024-03-11 | 144 | xsl144X01/primary_doc.xml | 0001836354-24-000002 | 001-36332 | 24740021 | 33 | 4519 | |||
| 2024-03-11 | 144 | xsl144X01/primary_doc.xml | 0001836354-24-000001 | 001-36332 | 24739958 | 33 | 4443 | |||
| 2024-03-11 | 144 | xsl144X01/primary_doc.xml | 0001972362-24-000397 | 001-36332 | 24739722 | 33 | 4456 | |||
| 2024-03-07 | S-3 | S-3 | 0001193125-24-062285 | 333-277753 | 24730975 | 33 | 330893 | |||
| 2024-03-07 | S-8 | S-8 | 0001193125-24-062277 | 333-277752 | 24730907 | 33 | 66243 | |||
| 2024-03-07 | S-8 POS | S-8 POS | 0001193125-24-062265 | 333-275315 | 24730790 | 33 | 30164 | |||
| 2024-03-07 | 10-K | 10-K | 0000950170-24-027933 | 001-36332 | 24730085 | 34 | 11369314 | 1 | 1 | |
| 2024-02-14 | SC 13G/A | SC 13G/A | 0001193125-24-036469 | 005-88182 | 24639831 | 34 | 59974 | |||
| 2024-02-13 | SC 13G | SCHEDULE 13G | 0001104659-24-020218 | 005-88182 | 24627311 | 34 | 13237 | |||
| 2024-02-13 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 7.01,9.01 | 0001157523-24-000230 | 001-36332 | 24625505 | 34 | 4437372 | 1 | 1 |
| 2024-01-29 | SC 13G | us01438t1060_012924.txt | 0001086364-24-005555 | 005-88182 | 24574886 | 34 | 13558 | |||
| 2024-01-04 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 8.01,9.01 | 0001157523-24-000014 | 001-36332 | 24509740 | 34 | 198397 | 1 | 1 |
| 2023-12-21 | 8-K | 8-K | 8.01 | 0001193125-23-301185 | 001-36332 | 231505357 | 34 | 142632 | 1 | 1 |
| 2023-12-19 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 7.01,8.01,9.01 | 0001157523-23-001841 | 001-36332 | 231495614 | 34 | 4122520 | 1 | 1 |
| 2023-11-28 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-23-283679 | 001-36332 | 231441889 | 34 | 3997323 | 1 | 1 |
| 2023-11-03 | S-8 | S-8 | 0001193125-23-270467 | 333-275315 | 231377028 | 33 | 120043 | |||
| 2023-11-03 | 10-Q | 10-Q | 0000950170-23-058829 | 001-36332 | 231376386 | 34 | 7498235 | 1 | 1 | |
| 2023-11-01 | 8-K | 8-K | 1.01 | 0001193125-23-267697 | 001-36332 | 231366542 | 34 | 160989 | 1 | 1 |
| 2023-10-19 | SC 13G/A | SC 13G/A | 0001193125-23-258680 | 005-88182 | 231333029 | 34 | 59873 | |||
| 2023-10-18 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-23-019546 | 11185 | ||||||
| 2023-10-16 | 8-K | 8-K | 8.01 | 0001193125-23-256532 | 001-36332 | 231326240 | 34 | 152914 | 1 | 1 |
| 2023-10-04 | SC 13G | SC 13G | 0001104659-23-106782 | 005-88182 | 231307756 | 34 | 83759 | |||
| 2023-09-11 | 4 | 4 | 0000950170-23-047530 | 15034 | ||||||
| 2023-09-11 | 4 | 4 | 0000950170-23-047497 | 6657 | ||||||
| 2023-08-24 | 4 | 4 | 0000950170-23-044379 | 6567 | ||||||
| 2023-08-03 | 10-Q | 10-Q | 0000950170-23-037934 | 001-36332 | 231139798 | 34 | 8163266 | 1 | 1 | |
| 2023-07-05 | 4 | 4 | 0000950170-23-031789 | 10029 | ||||||
| 2023-07-05 | 4 | 4 | 0000950170-23-031788 | 10098 | ||||||
| 2023-07-05 | 4 | 4 | 0000950170-23-031786 | 7747 | ||||||
| 2023-07-05 | 4 | 4 | 0000950170-23-031781 | 10024 | ||||||
| 2023-07-05 | 4 | 4 | 0000950170-23-031778 | 10148 | ||||||
| 2023-07-05 | 4 | 4 | 0000950170-23-031775 | 7681 | ||||||
| 2023-07-03 | 8-K | 8-K | 5.07 | 0001193125-23-181344 | 001-36332 | 231065350 | 34 | 158451 | 1 | 1 |
| 2023-06-29 | 4 | FORM 4 SUBMISSION | 0000899243-23-016709 | 6958 | ||||||
| 2023-06-29 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 7.01,8.01,9.01 | 0001157523-23-001047 | 001-36332 | 231054267 | 34 | 4010777 | 1 | 1 |
| 2023-06-27 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 7.01,8.01,9.01 | 0001157523-23-001035 | 001-36332 | 231043963 | 34 | 3092354 | 1 | 1 |
| 2023-06-21 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 8.01,9.01 | 0001157523-23-001018 | 001-36332 | 231030204 | 34 | 193047 | 1 | 1 |
| 2023-06-15 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 7.01,8.01,9.01 | 0001157523-23-000973 | 001-36332 | 231015935 | 34 | 4193513 | 1 | 1 |
| 2023-05-24 | ARS | ARS | 0001193125-23-151969 | 001-36332 | 23949992 | 34 | 3173499 | |||
| 2023-05-23 | DEF 14A | DEF 14A | 0001193125-23-151833 | 001-36332 | 23949219 | 34 | 1272160 | |||
| 2023-05-04 | 10-Q | 10-Q | 0000950170-23-017827 | 001-36332 | 23888564 | 34 | 6945510 | 1 | 1 | |
| 2023-05-04 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 2.02,8.01,9.01 | 0001157523-23-000722 | 001-36332 | 23886397 | 34 | 295275 | 1 | 1 |
| 2023-04-28 | 10-K/A | 10-K/A | 0001193125-23-126947 | 001-36332 | 23866236 | 34 | 620771 | 1 | 1 | |
| 2023-03-10 | 8-K | 8-K | 7.01 | 0001193125-23-067701 | 001-36332 | 23724438 | 34 | 141936 | 1 | 1 |
| 2023-03-09 | S-8 | S-8 | 0001193125-23-066127 | 333-270401 | 23719997 | 33 | 60190 | |||
| 2023-03-09 | 10-K | 10-K | 0000950170-23-006998 | 001-36332 | 23719667 | 34 | 13034419 | 1 | 1 | |
| 2023-03-09 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 2.02,8.01,9.01 | 0001157523-23-000419 | 001-36332 | 23718144 | 34 | 302530 | 1 | 1 |
| 2023-03-02 | 4 | FORM 4 SUBMISSION | 0000899243-23-006748 | 5569 | ||||||
| 2023-03-02 | 4 | FORM 4 SUBMISSION | 0000899243-23-006746 | 5615 | ||||||
| 2023-03-02 | 4 | FORM 4 SUBMISSION | 0000899243-23-006742 | 7545 | ||||||
| 2023-03-02 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 8.01,9.01 | 0001157523-23-000387 | 001-36332 | 23696386 | 34 | 199698 | 1 | 1 |
| 2023-02-14 | SC 13G/A | SC 13G/A | 0001193125-23-038732 | 005-88182 | 23627249 | 34 | 64761 | |||
| 2023-02-07 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 8.01,9.01 | 0001157523-23-000181 | 001-36332 | 23592754 | 34 | 199656 | 1 | 1 |
| 2023-02-03 | SC 13G/A | Aldeyra_Therapeutics_Inc.txt | 0000093751-23-000131 | 005-88182 | 23584402 | 34 | 8472 | |||
| 2022-12-27 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 1.01,2.03,8.01,9.01 | 0001157523-22-001788 | 001-36332 | 221486786 | 34 | 263207 | 1 | 1 |
| 2022-12-21 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 8.01,9.01 | 0001157523-22-001777 | 001-36332 | 221476483 | 34 | 192715 | 1 | 1 |
| 2022-12-01 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 8.01,9.01 | 0001157523-22-001698 | 001-36332 | 221437398 | 34 | 192511 | 1 | 1 |
| 2022-11-29 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 8.01,9.01 | 0001157523-22-001684 | 001-36332 | 221428370 | 34 | 192063 | 1 | 1 |
| 2022-11-10 | 10-Q | 10-Q | 0000950170-22-024434 | 001-36332 | 221376937 | 34 | 7630886 | 1 | 1 | |
| 2022-11-10 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 2.02,8.01,9.01 | 0001157523-22-001587 | 001-36332 | 221374890 | 34 | 342702 | 1 | 1 |
| 2022-10-06 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 7.01,8.01,9.01 | 0001157523-22-001289 | 001-36332 | 221297089 | 34 | 3271825 | 1 | 1 |
| 2022-09-14 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 8.01,9.01 | 0001157523-22-001225 | 001-36332 | 221242102 | 34 | 193864 | 1 | 1 |
| 2022-08-11 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-22-017733 | 11172 | ||||||
| 2022-08-10 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-22-017623 | 9190 | ||||||
| 2022-08-09 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-22-017559 | 9191 | ||||||
| 2022-08-08 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-22-017481 | 9190 | ||||||
| 2022-08-05 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-22-017393 | 9191 | ||||||
| 2022-08-05 | 10-Q | 10-Q | 0000950170-22-015115 | 001-36332 | 221140806 | 34 | 7310454 | 1 | 1 | |
| 2022-08-05 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 2.02,8.01,9.01 | 0001157523-22-001059 | 001-36332 | 221138571 | 34 | 325531 | 1 | 1 |
| 2022-08-04 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-22-017281 | 9193 | ||||||
| 2022-08-03 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-22-017202 | 9191 | ||||||
| 2022-08-02 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-22-017083 | 9195 | ||||||
| 2022-08-01 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-22-016987 | 9194 | ||||||
| 2022-07-19 | 4 | FORM 4 SUBMISSION | 0000899243-22-026346 | 6138 | ||||||
| 2022-07-19 | 4 | FORM 4 SUBMISSION | 0000899243-22-026345 | 5171 | ||||||
| 2022-07-19 | 4 | FORM 4 SUBMISSION | 0000899243-22-026344 | 9059 | ||||||
| 2022-07-12 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 7.01,8.01,9.01 | 0001157523-22-000837 | 001-36332 | 221078206 | 34 | 4286422 | 1 | 1 |
| 2022-07-08 | SC 13G | us01438t1060_070822.txt | 0000834237-22-010241 | 005-88182 | 221075009 | 34 | 12343 | |||
| 2022-06-27 | 4 | FORM 4 SUBMISSION | 0000899243-22-024133 | 5195 | ||||||
| 2022-06-27 | 4 | FORM 4 SUBMISSION | 0000899243-22-024132 | 5290 | ||||||
| 2022-06-09 | 4 | FORM 4 SUBMISSION | 0000899243-22-021638 | 10542 | ||||||
| 2022-06-09 | 4 | FORM 4 SUBMISSION | 0000899243-22-021637 | 8103 | ||||||
| 2022-06-09 | 4 | FORM 4 SUBMISSION | 0000899243-22-021634 | 10608 | ||||||
| 2022-06-09 | 4 | FORM 4 SUBMISSION | 0000899243-22-021632 | 10543 | ||||||
| 2022-06-09 | 4 | FORM 4 SUBMISSION | 0000899243-22-021633 | 10673 | ||||||
| 2022-06-09 | 4 | FORM 4 SUBMISSION | 0000899243-22-021626 | 8043 | ||||||
| 2022-06-08 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 5.07,7.01,8.01,9.01 | 0001157523-22-000745 | 001-36332 | 221002578 | 34 | 2806315 | 1 | 1 |
| 2022-05-24 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 8.01,9.01 | 0001157523-22-000678 | 001-36332 | 22953976 | 34 | 189148 | 1 | 1 |
| 2022-05-18 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 8.01,9.01 | 0001157523-22-000653 | 001-36332 | 22937107 | 34 | 198266 | 1 | 1 |
| 2022-05-13 | 3 | FORM 3 SUBMISSION | 0000899243-22-018011 | 10785 | ||||||
| 2022-05-05 | 10-Q | 10-Q | 0000950170-22-007890 | 001-36332 | 22897112 | 34 | 6690767 | 1 | 1 | |
| 2022-05-05 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 2.02,8.01,9.01 | 0001157523-22-000561 | 001-36332 | 22894014 | 34 | 302147 | 1 | 1 |
| 2022-04-28 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 5.02,9.01 | 0001157523-22-000502 | 001-36332 | 22866663 | 34 | 184146 | 1 | 1 |
| 2022-04-25 | DEFA14A | DEFA14A | 0001193125-22-117594 | 001-36332 | 22849947 | 34 | 936298 | |||
| 2022-04-25 | DEF 14A | DEF 14A | 0001193125-22-117585 | 001-36332 | 22849925 | 34 | 1052050 | |||
| 2022-04-01 | 4 | FORM 4 SUBMISSION | 0000899243-22-013176 | 10174 | ||||||
| 2022-04-01 | 4 | FORM 4 SUBMISSION | 0000899243-22-013174 | 7736 | ||||||
| 2022-04-01 | 4 | FORM 4 SUBMISSION | 0000899243-22-013173 | 8675 | ||||||
| 2022-03-29 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-22-087464 | 001-36332 | 22777485 | 34 | 21443944 | 1 | 1 |
| 2022-03-17 | S-8 | S-8 | 0001193125-22-078435 | 333-263660 | 22749793 | 33 | 57960 | |||
| 2022-03-17 | 10-K | 10-K | 0000950170-22-004111 | 001-36332 | 22749708 | 34 | 13696143 | 1 | 1 | |
| 2022-03-17 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 2.02,8.01,9.01 | 0001157523-22-000341 | 001-36332 | 22746700 | 34 | 347130 | 1 | 1 |
| 2022-02-14 | SC 13G/A | SC 13G/A | 0001193125-22-041509 | 005-88182 | 22630797 | 34 | 70529 | |||
| 2022-02-09 | SC 13G | ALDEYRA_THERAPEUTICS_INC.txt | 0000093751-22-000049 | 005-88182 | 22607965 | 34 | 8551 | |||
| 2022-02-04 | SC 13G | us01438t1060_020422.txt | 0000834237-22-007296 | 005-88182 | 22593563 | 34 | 13301 | |||
| 2022-01-04 | SC 13G/A | SCHEDULE 13G/A | 0000904454-22-000002 | 005-88182 | 22504344 | 34 | 34892 | |||
| 2021-12-21 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-21-363014 | 001-36332 | 211506823 | 34 | 4321849 | 1 | 1 |
| 2021-11-09 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 8.01,9.01 | 0001157523-21-001374 | 001-36332 | 211389969 | 34 | 190969 | 1 | 1 |
| 2021-11-02 | 8-K | 8-K | 8.01,9.01 | 0001193125-21-316254 | 001-36332 | 211369350 | 34 | 175671 | 1 | 1 |
| 2021-10-28 | 10-Q | 10-Q | 0000950170-21-002456 | 001-36332 | 211358192 | 34 | 6611657 | 1 | 1 | |
| 2021-10-28 | 8-K | ALDEYRA THERAPEUTICS, INC. 8-K | 2.02,8.01,9.01 | 0001157523-21-001271 | 001-36332 | 211355014 | 34 | 323903 | 1 | 1 |
| 2021-08-05 | 10-Q | 10-Q | 0000950170-21-000925 | 001-36332 | 211148098 | 34 | 6335823 | 1 | 1 | |
| 2021-08-05 | 8-K | 8-K | 2.02,8.01,9.01 | 0001193125-21-236970 | 001-36332 | 211146297 | 34 | 239295 | 1 | 1 |
| 2021-06-10 | 4 | FORM 4 SUBMISSION | 0000899243-21-023013 | 10670 | ||||||
| 2021-06-10 | 4 | FORM 4 SUBMISSION | 0000899243-21-023012 | 10608 | ||||||
| 2021-06-10 | 4 | FORM 4 SUBMISSION | 0000899243-21-023011 | 8102 | ||||||
| 2021-06-10 | 4 | FORM 4 SUBMISSION | 0000899243-21-023010 | 10542 | ||||||
| 2021-06-10 | 4 | FORM 4 SUBMISSION | 0000899243-21-023009 | 8042 | ||||||
| 2021-06-10 | 4 | FORM 4 SUBMISSION | 0000899243-21-023007 | 10540 | ||||||
| 2021-06-09 | 8-K | 8-K | 5.07 | 0001193125-21-186792 | 001-36332 | 211005495 | 34 | 155343 | 1 | 1 |
| 2021-05-06 | 10-Q | 10-Q | 0001564590-21-024943 | 001-36332 | 21897710 | 34 | 6083565 | 1 | 1 | |
| 2021-05-06 | 8-K | 8-K | 2.02,8.01,9.01 | 0001193125-21-152486 | 001-36332 | 21895779 | 34 | 238082 | 1 | 1 |
| 2021-05-04 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-21-004109 | 8738 | ||||||
| 2021-04-29 | 424B5 | 424B5 | 0001193125-21-140810 | 333-254175 | 21872024 | 33 | 490100 | |||
| 2021-04-29 | 8-K | 8-K | 1.01,8.01,9.01 | 0001193125-21-140533 | 001-36332 | 21871057 | 34 | 519402 | 1 | 1 |
| 2021-04-27 | 424B5 | 424B5 | 0001193125-21-134419 | 333-254175 | 21859774 | 33 | 490072 | |||
| 2021-04-27 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-21-132903 | 001-36332 | 21855984 | 34 | 6080243 | 1 | 1 |
| 2021-04-21 | 8-K | 8-K | 1.01,2.03,9.01 | 0001193125-21-124890 | 001-36332 | 21842038 | 34 | 203913 | 1 | 1 |
| 2021-04-15 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2021-04-15 16:00:00 | 9999999995-21-001448 | 333-254175 | 21830010 | 33 | 1916 | ||
| 2021-04-14 | 4 | FORM 4 SUBMISSION | 0000899243-21-015839 | 5594 | ||||||
| 2021-04-14 | 4 | FORM 4 SUBMISSION | 0000899243-21-015838 | 5579 | ||||||
| 2021-04-14 | 4 | FORM 4 SUBMISSION | 0000899243-21-015837 | 7553 | ||||||
| 2021-04-14 | DEFA14A | DEFA14A | 0001564590-21-018848 | 001-36332 | 21826527 | 34 | 245376 | |||
| 2021-04-14 | DEF 14A | DEF 14A | 0001564590-21-018847 | 001-36332 | 21826494 | 34 | 888370 | |||
| 2021-04-13 | CORRESP | filename1.htm | 0001193125-21-114658 | 7811 | ||||||
| 2021-03-17 | UPLOAD | filename1.pdf | 0000000000-21-003224 | 40423 | ||||||
| 2021-03-11 | S-3 | S-3 | 0001193125-21-077943 | 333-254175 | 21734121 | 33 | 623816 | |||
| 2021-03-11 | S-8 | S-8 | 0001193125-21-077845 | 333-254144 | 21733639 | 33 | 45502 | |||
| 2021-03-11 | 10-K | 10-K | 0001564590-21-012501 | 001-36332 | 21733353 | 34 | 9751664 | 1 | 1 | |
| 2021-03-11 | 8-K | 8-K | 2.02,8.01,9.01 | 0001193125-21-077046 | 001-36332 | 21731865 | 34 | 240543 | 1 | 1 |
| 2021-02-16 | SC 13G/A | SC 13G/A | 0001193125-21-044700 | 005-88182 | 21637164 | 34 | 64266 | |||
| 2021-02-16 | SC 13G/A | aldeyra13ga3-021621.htm | 0001013594-21-000156 | 005-88182 | 21636702 | 34 | 68208 | |||
| 2021-02-12 | SC 13G/A | SC 13G/A | 0001193125-21-040123 | 005-88182 | 21623014 | 34 | 107092 | |||
| 2021-01-25 | 8-K | 8-K | 5.02 | 0001193125-21-016281 | 001-36332 | 21549990 | 34 | 143943 | 1 | 1 |
| 2021-01-21 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-21-000506 | 8737 | ||||||
| 2021-01-14 | 424B5 | 424B5 | 0001193125-21-009091 | 333-226266 | 21529159 | 33 | 919717 | |||
| 2021-01-14 | 8-K | 8-K | 1.01,8.01,9.01 | 0001193125-21-008625 | 001-36332 | 21527512 | 34 | 516187 | 1 | 1 |
| 2021-01-13 | 424B5 | 424B5 | 0001193125-21-008136 | 333-226266 | 21526169 | 33 | 920942 | |||
| 2021-01-11 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-21-000275 | 14806 | ||||||
| 2021-01-07 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-21-003740 | 001-36332 | 21513009 | 34 | 7554892 | 1 | 1 |
| 2020-12-18 | 3 | FORM 3 SUBMISSION | 0000899243-20-034529 | 11872 | ||||||
| 2020-11-05 | 10-Q | 10-Q | 0001564590-20-051290 | 001-36332 | 201290378 | 34 | 6710068 | 1 | 1 | |
| 2020-11-05 | 8-K | 8-K | 2.02,8.01,9.01 | 0001193125-20-286220 | 001-36332 | 201288671 | 34 | 250172 | 1 | 1 |
| 2020-08-06 | 10-Q | 10-Q | 0001564590-20-037714 | 001-36332 | 201081551 | 34 | 6789998 | 1 | 1 | |
| 2020-08-06 | 8-K | 8-K | 2.02,8.01,9.01 | 0001193125-20-211319 | 001-36332 | 201079809 | 34 | 111882 | ||
| 2020-07-14 | 8-K | 8-K | 8.01,9.01 | 0001193125-20-192321 | 001-36332 | 201026366 | 34 | 43905 | ||
| 2020-07-13 | 4 | FORM 4 SUBMISSION | 0000899243-20-019004 | 8950 | ||||||
| 2020-07-13 | SC 13G/A | SC 13G/A | 0001193125-20-191905 | 005-88182 | 201025505 | 34 | 64471 | |||
| 2020-07-10 | SC 13G/A | us01438t1060_071020.txt | 0000834237-20-010003 | 005-88182 | 201022201 | 34 | 12315 | |||
| 2020-07-07 | 8-K | 8-K | 8.01,9.01 | 0001193125-20-188425 | 001-36332 | 201015276 | 34 | 45762 | ||
| 2020-06-12 | 8-K | 8-K | 5.07 | 0001193125-20-167714 | 001-36332 | 20960456 | 34 | 33699 | ||
| 2020-06-11 | 4 | FORM 4 SUBMISSION | 0000899243-20-016185 | 10523 | ||||||
| 2020-06-11 | 4 | FORM 4 SUBMISSION | 0000899243-20-016183 | 5631 | ||||||
| 2020-06-11 | 4 | FORM 4 SUBMISSION | 0000899243-20-016182 | 10669 | ||||||
| 2020-06-11 | 4 | FORM 4 SUBMISSION | 0000899243-20-016181 | 10541 | ||||||
| 2020-06-11 | 4 | FORM 4 SUBMISSION | 0000899243-20-016180 | 8042 | ||||||
| 2020-06-11 | 4 | FORM 4 SUBMISSION | 0000899243-20-016177 | 8132 | ||||||
| 2020-06-11 | 4 | PRIMARY DOCUMENT | 0000904454-20-000398 | 10306 | ||||||
| 2020-06-04 | 8-K | 8-K | 8.01,9.01 | 0001193125-20-160151 | 001-36332 | 20941933 | 34 | 51668 | ||
| 2020-05-20 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-20-146738 | 001-36332 | 20895707 | 34 | 7393253 | ||
| 2020-05-07 | 10-Q | 10-Q | 0001564590-20-022912 | 001-36332 | 20856903 | 34 | 5596788 | 1 | ||
| 2020-05-07 | 8-K | 8-K | 2.02,8.01,9.01 | 0001193125-20-135600 | 001-36332 | 20854569 | 34 | 65171 | ||
| 2020-05-01 | 8-K | 8-K | 5.03,9.01 | 0001193125-20-131009 | 001-36332 | 20841210 | 34 | 126913 | ||
| 2020-04-27 | DEFA14A | DEFA14A | 0001564590-20-018879 | 001-36332 | 20821248 | 34 | 461922 | |||
| 2020-04-27 | DEF 14A | DEF 14A | 0001564590-20-018862 | 001-36332 | 20820874 | 34 | 1261782 | |||
| 2020-04-14 | 8-K | 8-K | 8.01,9.01 | 0001193125-20-105860 | 001-36332 | 20790113 | 34 | 42566 | ||
| 2020-03-17 | 4 | FORM 4 SUBMISSION | 0000899243-20-008616 | 4791 | ||||||
| 2020-03-12 | S-8 | S-8 | 0001193125-20-071672 | 333-237129 | 20709501 | 33 | 48137 | |||
| 2020-03-12 | 10-K | 10-K | 0001564590-20-010493 | 001-36332 | 20709224 | 34 | 8492369 | 1 | ||
| 2020-03-12 | 8-K | 8-K | 2.02,5.02,8.01,9.01 | 0001193125-20-070920 | 001-36332 | 20707155 | 34 | 114537 | ||
| 2020-03-06 | 4/A | FORM 4/A SUBMISSION | 0000899243-20-007448 | 7790 | ||||||
| 2020-03-06 | 4/A | FORM 4/A SUBMISSION | 0000899243-20-007447 | 8000 | ||||||
| 2020-03-04 | 4 | FORM 4 SUBMISSION | 0000899243-20-007067 | 7566 | ||||||
| 2020-03-04 | 4 | FORM 4 SUBMISSION | 0000899243-20-007064 | 7776 | ||||||
| 2020-03-04 | 4 | FORM 4 SUBMISSION | 0000899243-20-007060 | 10173 | ||||||
| 2020-02-25 | SC 13G | SC 13G | 0001193125-20-047397 | 005-88182 | 20647748 | 34 | 133068 | |||
| 2020-02-24 | 8-K | 8-K | 8.01,9.01 | 0001193125-20-045535 | 001-36332 | 20642127 | 34 | 51290 | ||
| 2020-02-14 | SC 13G/A | SC 13G/A | 0001193125-20-038085 | 005-88182 | 20619046 | 34 | 66104 | |||
| 2020-02-13 | SC 13G/A | DECEMBER 31, 2019 | 0001013594-20-000132 | 005-88182 | 20607471 | 34 | 85215 | |||
| 2020-02-12 | SC 13G/A | ALDEYRA THERAPEUTICS, INC. | 0000902664-20-000962 | 005-88182 | 20604371 | 34 | 103835 | |||
| 2020-02-07 | SC 13G/A | filing.txt | 0000315066-20-000826 | 005-88182 | 20585460 | 34 | 8571 | |||
| 2020-02-07 | SC 13G | us01438t1060_020620.txt | 0000834237-20-008145 | 005-88182 | 20584789 | 34 | 13258 | |||
| 2020-01-15 | 4 | FORM 4 SUBMISSION | 0000899243-20-001261 | 5503 | ||||||
| 2020-01-15 | 3 | FORM 3 SUBMISSION | 0000899243-20-001258 | 3118 | ||||||
| 2020-01-14 | 8-K | 8-K | 5.02,9.01 | 0001193125-20-006782 | 001-36332 | 20525013 | 34 | 40247 | ||
| 2020-01-10 | SC 13G/A | SCHEDULE 13G-A FOR ALDEYRA THERAPEUTICS, INC. BY DOMAIN PARTNERS VI, L.P. | 0000904454-20-000020 | 005-88182 | 20519108 | 34 | 33850 | |||
| 2019-12-18 | 4 | FORM 4 SUBMISSION | 0000899243-19-029509 | 4730 | ||||||
| 2019-12-03 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-19-304808 | 001-36332 | 191264651 | 34 | 8899913 | ||
| 2019-11-07 | 10-Q | 10-Q | 0001564590-19-041846 | 001-36332 | 191201102 | 34 | 5627951 | 1 | ||
| 2019-11-07 | 8-K | 8-K | 2.02,8.01,9.01 | 0001193125-19-286617 | 001-36332 | 191198125 | 34 | 104853 | ||
| 2019-10-31 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-19-279627 | 001-36332 | 191182119 | 34 | 6066824 | ||
| 2019-10-02 | 4 | FORM 4 SUBMISSION | 0000899243-19-024582 | 5488 | ||||||
| 2019-09-27 | SC 13G | ALDEYRA THERAPEUTICS, INC. | 0000902664-19-003845 | 005-88182 | 191120605 | 34 | 107360 | |||
| 2019-09-25 | 4 | FORM 4 SUBMISSION | 0000899243-19-024225 | 5488 | ||||||
| 2019-09-24 | 8-K | 8-K | 8.01,9.01 | 0001193125-19-252836 | 001-36332 | 191109220 | 34 | 38552 | ||
| 2019-09-20 | 4 | FORM 4 SUBMISSION | 0000899243-19-023982 | 5281 | ||||||
| 2019-09-19 | 4 | FORM 4 SUBMISSION | 0000899243-19-023923 | 4636 | ||||||
| 2019-09-17 | 4/A | FORM 4/A SUBMISSION | 0000899243-19-023735 | 7044 | ||||||
| 2019-09-17 | 4 | FORM 4 SUBMISSION | 0000899243-19-023719 | 4790 | ||||||
| 2019-09-17 | 4 | FORM 4 SUBMISSION | 0000899243-19-023718 | 6252 | ||||||
| 2019-09-16 | 4 | FORM 4 SUBMISSION | 0000899243-19-023628 | 5195 | ||||||
| 2019-09-13 | 4 | FORM 4 SUBMISSION | 0000899243-19-023539 | 7416 | ||||||
| 2019-09-11 | 4 | FORM 4 SUBMISSION | 0000899243-19-023317 | 7545 | ||||||
| 2019-09-11 | 4 | FORM 4 SUBMISSION | 0000899243-19-023315 | 7416 | ||||||
| 2019-09-10 | 4 | FORM 4 SUBMISSION | 0000899243-19-023265 | 5426 | ||||||
| 2019-09-09 | 4 | FORM 4 SUBMISSION | 0000899243-19-023129 | 4934 | ||||||
| 2019-09-09 | 4 | FORM 4 SUBMISSION | 0000899243-19-023128 | 4943 | ||||||
| 2019-09-03 | 8-K | 8-K | 8.01 | 0001193125-19-235793 | 001-36332 | 191070837 | 34 | 19339 | ||
| 2019-08-09 | 10-Q | 10-Q | 0001564590-19-031031 | 001-36332 | 191011351 | 34 | 5326238 | 1 | ||
| 2019-08-08 | 8-K | 8-K | 2.02,8.01,9.01 | 0001193125-19-216016 | 001-36332 | 191007448 | 34 | 102017 | ||
| 2019-06-25 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-19-180730 | 001-36332 | 19916930 | 34 | 4167287 | ||
| 2019-06-06 | 4 | FORM 4 SUBMISSION | 0000899243-19-015824 | 10550 | ||||||
| 2019-06-06 | 4 | FORM 4 SUBMISSION | 0000899243-19-015822 | 8150 | ||||||
| 2019-06-06 | 4 | FORM 4 SUBMISSION | 0000899243-19-015821 | 10693 | ||||||
| 2019-06-06 | 4 | FORM 4 SUBMISSION | 0000899243-19-015820 | 10565 | ||||||
| 2019-06-06 | 4 | FORM 4 SUBMISSION | 0000899243-19-015819 | 8060 | ||||||
| 2019-06-06 | 4 | PRIMARY DOCUMENT | 0000904454-19-000466 | 10306 | ||||||
| 2019-06-06 | 8-K | 8-K | 5.07,7.01,9.01 | 0001193125-19-166628 | 001-36332 | 19881483 | 34 | 15247229 | ||
| 2019-05-10 | 10-Q | 10-Q | 0001564590-19-018542 | 001-36332 | 19815025 | 34 | 4860514 | 1 | ||
| 2019-05-09 | 8-K | 8-K | 2.02,9.01 | 0001193125-19-142173 | 001-36332 | 19808747 | 34 | 90009 | ||
| 2019-04-22 | DEFA14A | DEFA14A | 0001564590-19-012254 | 001-36332 | 19759547 | 34 | 94300 | |||
| 2019-04-22 | DEF 14A | DEF 14A | 0001564590-19-012248 | 001-36332 | 19759491 | 34 | 1381480 | |||
| 2019-03-28 | 4 | PRIMARY DOCUMENT | 0000904454-19-000337 | 7240 | ||||||
| 2019-03-26 | 8-K | 8-K | 1.01,2.03,7.01,8.01,9.01 | 0001193125-19-085920 | 001-36332 | 19704114 | 34 | 9254481 | ||
| 2019-03-08 | S-8 | S-8 | 0001193125-19-069189 | 333-230161 | 19669566 | 33 | 50138 | |||
| 2019-03-08 | 10-K | 10-K | 0001564590-19-006997 | 001-36332 | 19669147 | 34 | 7143800 | 1 | ||
| 2019-03-08 | 8-K | 8-K | 2.02,9.01 | 0001193125-19-067948 | 001-36332 | 19667593 | 34 | 83223 | ||
| 2019-03-07 | 4 | FORM 4 SUBMISSION | 0000899243-19-006734 | 5600 | ||||||
| 2019-03-07 | 4 | FORM 4 SUBMISSION | 0000899243-19-006732 | 7564 | ||||||
| 2019-03-07 | 4 | FORM 4 SUBMISSION | 0000899243-19-006730 | 7700 | ||||||
| 2019-03-07 | 4 | FORM 4 SUBMISSION | 0000899243-19-006729 | 10360 | ||||||
| 2019-02-28 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-19-055552 | 001-36332 | 19640416 | 34 | 20893401 | ||
| 2019-02-14 | SC 13G/A | SC 13G/A | 0001193125-19-040933 | 005-88182 | 19606922 | 34 | 68884 | |||
| 2019-02-14 | SC 13G/A | FEBRUARY 14, 2019 | 0001013594-19-000164 | 005-88182 | 19603049 | 34 | 93904 | |||
| 2019-02-13 | SC 13G/A | SC-13G/A | 0001178913-19-000432 | 005-88182 | 19598284 | 34 | 133745 | |||
| 2019-02-13 | SC 13G/A | filing.txt | 0000315066-19-000826 | 005-88182 | 19594484 | 34 | 8513 | |||
| 2019-02-11 | D | xslFormDX01/primary_doc.xml | 06b | 0001582746-19-000001 | 021-332606 | 19586488 | 33 | 14716 | ||
| 2019-01-29 | 8-K | 8-K | 1.01,2.01,3.02,8.01,9.01 | 0001193125-19-019770 | 001-36332 | 19547157 | 34 | 613361 | ||
| 2019-01-22 | SC 13G/A | SCHEDULE 13G-A FOR ALDEYRA THERAPEUTICS, INC. BY JOHNSON & JOHNSON | 0000904454-19-000069 | 005-88182 | 19534752 | 34 | 59747 | |||
| 2018-12-28 | 424B5 | 424B5 | 0001193125-18-360963 | 333-226266 | 181257629 | 33 | 912817 | |||
| 2018-12-28 | 8-K | 8-K | 1.01,9.01 | 0001193125-18-360931 | 001-36332 | 181257528 | 34 | 226339 | ||
| 2018-11-21 | 8-K | 8-K | 1.02 | 0001193125-18-331873 | 001-36332 | 181197017 | 34 | 15087 | ||
| 2018-11-14 | 10-Q | FORM 10-Q | 0001193125-18-326837 | 001-36332 | 181185131 | 34 | 2974247 | 1 | ||
| 2018-11-14 | 8-K | 8-K | 2.02,9.01 | 0001193125-18-326140 | 001-36332 | 181180453 | 34 | 89734 | ||
| 2018-10-04 | CT ORDER | filename1.pdf | 20181004,20181004 | 9999999997-18-008382 | 001-36332 | 181107746 | 34 | 14046 | ||
| 2018-09-28 | 8-K | 8-K | 1.01,8.01,9.01 | 0001193125-18-287591 | 001-36332 | 181094707 | 34 | 276828 | ||
| 2018-09-28 | 424B5 | 424B5 | 0001193125-18-287518 | 333-226266 | 181094574 | 33 | 748153 | |||
| 2018-09-26 | 424B5 | 424(B)(5) | 0001193125-18-283947 | 333-226266 | 181088076 | 33 | 746868 | |||
| 2018-09-26 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-18-283160 | 001-36332 | 181086872 | 34 | 11760282 | ||
| 2018-09-25 | 8-K | 8-K | 8.01,9.01 | 0001193125-18-281789 | 001-36332 | 181084717 | 34 | 509697 | ||
| 2018-08-09 | 10-Q | FORM 10-Q | 0001193125-18-244346 | 001-36332 | 181005261 | 34 | 2938197 | 1 | ||
| 2018-08-09 | 8-K | 8-K | 2.02,9.01 | 0001193125-18-243481 | 001-36332 | 181003432 | 34 | 88837 | ||
| 2018-08-01 | 4 | FORM 4 SUBMISSION | 0000899243-18-020988 | 5738 | ||||||
| 2018-08-01 | 3 | FORM 3 SUBMISSION | 0000899243-18-020978 | 3166 | ||||||
| 2018-08-01 | 3 | FORM 3 SUBMISSION | 0000899243-18-020972 | 4528 | ||||||
| 2018-07-31 | 8-K | 8-K | 5.02,9.01 | 0001193125-18-232408 | 001-36332 | 18979499 | 34 | 41691 | ||
| 2018-07-27 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2018-07-27 16:30:00 | 9999999995-18-001924 | 333-226266 | 18975974 | 33 | 1916 | ||
| 2018-07-26 | UPLOAD | filename1.pdf | 0000000000-18-022951 | 44921 | ||||||
| 2018-07-25 | CORRESP | filename1.htm | 0001193125-18-225751 | 7081 | ||||||
| 2018-07-20 | S-3 | S-3 | 0001193125-18-222562 | 333-226266 | 18962746 | 33 | 1037175 | |||
| 2018-06-26 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-18-203119 | 001-36332 | 18918296 | 34 | 14501958 | ||
| 2018-06-11 | 4 | PRIMARY DOCUMENT | 0000904454-18-000424 | 10293 | ||||||
| 2018-06-08 | 4 | FORM 4 SUBMISSION | 0000899243-18-015771 | 10547 | ||||||
| 2018-06-08 | 4 | FORM 4 SUBMISSION | 0000899243-18-015770 | 10704 | ||||||
| 2018-06-08 | 4 | FORM 4 SUBMISSION | 0000899243-18-015769 | 8057 | ||||||
| 2018-06-08 | 4 | FORM 4 SUBMISSION | 0000899243-18-015767 | 8151 | ||||||
| 2018-06-08 | 4 | FORM 4 SUBMISSION | 0000899243-18-015766 | 10565 | ||||||
| 2018-06-08 | 8-K | FORM 8-K | 5.07 | 0001193125-18-188147 | 001-36332 | 18889901 | 34 | 25034 | ||
| 2018-05-15 | 10-Q | FORM 10-Q | 0001193125-18-164070 | 001-36332 | 18836367 | 34 | 2513563 | 1 | ||
| 2018-05-15 | 8-K | FORM 8-K | 2.02,9.01 | 0001193125-18-163406 | 001-36332 | 18833090 | 34 | 73128 |
One latest value per concept from companyfacts (311 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 60.36M | 2026-11-03 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 231.90M | 2025-06-30 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| ecd | NonPeoNeoAvgCompActuallyPaidAmt | NonPeoNeoAvgCompActuallyPaidAmt | USD | 801,510 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-27 | 0001193125-26-182099 | ||
| ecd | NonPeoNeoAvgTotalCompAmt | NonPeoNeoAvgTotalCompAmt | USD | 848,168 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-27 | 0001193125-26-182099 | ||
| ecd | PeoActuallyPaidCompAmt | PeoActuallyPaidCompAmt | USD | 4.29M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-27 | 0001193125-26-182099 | ||
| ecd | PeoTotalCompAmt | PeoTotalCompAmt | USD | 4.70M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-27 | 0001193125-26-182099 | ||
| ecd | TotalShareholderRtnAmt | TotalShareholderRtnAmt | USD | 74.43 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-27 | 0001193125-26-182099 | ||
| invest | InvestmentWarrantsExercisePrice | Investment Warrants, Exercise Price | USD | 0.125 | 2015-01-21 | 2018 | Q3 | 10-Q | 2018-11-14 | 0001193125-18-326837 | |
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 144,443 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | AccrualForTaxesOtherThanIncomeTaxesCurrent | Accrual for Taxes Other than Income Taxes, Current | USD | 106,886 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 | |
| us-gaap | AccruedLiabilitiesAndOtherLiabilities | Accrued Liabilities and Other Liabilities | USD | 908,724 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 1.56M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | AccruedPayrollTaxesCurrent | Accrued Payroll Taxes, Current | USD | 444,786 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 | |
| us-gaap | AccruedProfessionalFeesCurrent | Accrued Professional Fees, Current | USD | 41,985 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 62.47M | 2015-03-31 | 2015 | Q1 | 10-Q | 2015-05-14 | 0001193125-15-187962 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 531.78M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation | USD | 532,951 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-02-28 | 0000950170-25-030102 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 3.56M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 1.77M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | AmortizationOfDebtDiscountPremium | Amortization of Debt Discount (Premium) | USD | 50,368 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 8.95M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | AreaOfLand | Area of Land | sqft | 4,067 | 2026-07-28 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | Assets | Assets | USD | 43.38M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 42.92M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | AssetsFairValueDisclosure | Assets, Fair Value Disclosure | USD | 38.54M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | AvailableForSaleDebtSecuritiesGrossUnrealizedLoss | Debt Securities, Available-for-sale, Unrealized Loss | USD | 103,938 | 2022-01-01 | 2022-12-31 | 2023 | Q3 | 10-Q | 2023-11-03 | 0000950170-23-058829 |
| us-gaap | AvailableForSaleSecurities | Available-for-sale Securities | USD | 28.93M | 2019-12-31 | 2020 | FY | 10-K | 2021-03-11 | 0001564590-21-012501 | |
| us-gaap | AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax | USD | 0 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-29 | 0001193125-18-102077 | |
| us-gaap | AvailableForSaleSecuritiesCurrent | Available-for-sale Securities, Current | USD | 46.24M | 2018-12-31 | 2018 | FY | 10-K | 2019-03-08 | 0001564590-19-006997 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 29.99M | 2022-12-31 | 2023 | Q3 | 10-Q | 2023-11-03 | 0000950170-23-058829 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesCurrent | Debt Securities, Available-for-sale, Current | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued | Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares | 1.16M | 2019-01-28 | 2020 | FY | 10-K | 2021-03-11 | 0001564590-21-012501 | |
| us-gaap | Cash | Cash | USD | 33.37M | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-05 | 0000950170-22-015115 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 70.04M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | CashAndCashEquivalentsPeriodIncreaseDecrease | Cash and Cash Equivalents, Period Increase (Decrease) | USD | -7.96M | 2019-01-01 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-09 | 0001564590-19-031031 |
| us-gaap | CashCashEquivalentsAndShortTermInvestments | Cash, Cash Equivalents, and Short-term Investments | USD | 44.43M | 2019-12-31 | 2020 | FY | 10-K | 2021-03-11 | 0001564590-21-012501 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 40.97M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -29.07M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 | Class of Warrant or Right, Exercise Price of Warrants or Rights | USD/shares | 10 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-08 | 0001564590-19-006997 | |
| us-gaap | ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights | Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 211,528 | 2015-01-21 | 2018 | Q3 | 10-Q | 2018-11-14 | 0001193125-18-326837 | |
| us-gaap | ClassOfWarrantOrRightOutstanding | Class of Warrant or Right, Outstanding | shares | 40,300 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-08 | 0001564590-19-006997 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 150.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 60.36M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 60.36M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 60,357 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -12.67M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ConversionOfStockAmountConverted1 | Conversion of Stock, Amount Converted | USD | -38.65M | 2014-01-01 | 2014-06-30 | 2014 | Q2 | 10-Q | 2014-08-07 | 0001193125-14-300661 |
| us-gaap | ConvertibleNotesPayableCurrent | Convertible Notes Payable, Current | USD | 85,000 | 2013-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 | |
| us-gaap | ConvertiblePreferredStockConvertedToOtherSecurities | Convertible Preferred Stock Converted to Other Securities | USD | -38.65M | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 |
| us-gaap | ConvertiblePreferredStockSharesIssuedUponConversion | Convertible Preferred Stock, Shares Issued upon Conversion | shares | 3.64M | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 | |
| us-gaap | CurrentFederalTaxExpenseBenefit | Current Federal Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | CurrentStateAndLocalTaxExpenseBenefit | Current State and Local Tax Expense (Benefit) | USD | 30,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | DebtConversionConvertedInstrumentAmount1 | Debt Conversion, Converted Instrument, Amount | USD | 170,000 | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 |
| us-gaap | DebtConversionConvertedInstrumentSharesIssued1 | Debt Conversion, Converted Instrument, Shares Issued | shares | 21,250 | 2014-05-08 | 2014-05-31 | 2014 | Q2 | 10-Q | 2014-08-07 | 0001193125-14-300661 |
| us-gaap | DebtCurrent | Debt, Current | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | DebtInstrumentAnnualPrincipalPayment | Debt Instrument, Annual Principal Payment | USD | 15.00M | 2026-04-01 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | DebtInstrumentBasisSpreadOnVariableRate1 | Debt Instrument, Basis Spread on Variable Rate | pure | 0.028 | 2012-04-12 | 2014 | Q2 | 10-Q | 2014-08-07 | 0001193125-14-300661 | |
| us-gaap | DebtInstrumentCarryingAmount | Long-term Debt, Gross | USD | 14.67M | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-07 | 0001564590-20-022912 | |
| us-gaap | DebtInstrumentFaceAmount | Debt Instrument, Face Amount | USD | 170,000 | 2013-10-31 | 2014 | Q2 | 10-Q | 2014-08-07 | 0001193125-14-300661 | |
| us-gaap | DebtInstrumentFairValue | Debt Instrument, Fair Value Disclosure | USD | 29.88M | 2022-12-31 | 2023 | Q3 | 10-Q | 2023-11-03 | 0000950170-23-058829 | |
| us-gaap | DebtInstrumentInterestRateStatedPercentage | Debt Instrument, Interest Rate, Stated Percentage | pure | 0.06 | 2013-10-31 | 2014 | Q2 | 10-Q | 2014-08-07 | 0001193125-14-300661 | |
| us-gaap | DebtInstrumentUnamortizedDiscount | Debt Instrument, Unamortized Discount | USD | 133,453 | 2015-03-31 | 2015 | Q1 | 10-Q | 2015-05-14 | 0001193125-15-187962 | |
| us-gaap | DeferredCosts | Deferred Costs, Noncurrent | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredCostsAndOtherAssets | Deferred Costs and Other Assets | USD | 2.51M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredFederalIncomeTaxExpenseBenefit | Deferred Federal Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | DeferredIncomeTaxesAndTaxCredits | Deferred Income Taxes and Tax Credits | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0000950170-22-004111 |
| us-gaap | DeferredIncomeTaxLiabilities | Deferred Tax Liabilities, Gross | USD | 16,206 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-08 | 0001564590-19-006997 | |
| us-gaap | DeferredLongTermLiabilityCharges | Deferred Long-term Liability Charges | USD | 6.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | DeferredOfferingCosts | Deferred Offering Costs | USD | 74,335 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-05 | 0000950170-21-000925 | |
| us-gaap | DeferredRevenueCurrent | Deferred Revenue, Current | USD | 6.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredStateAndLocalIncomeTaxExpenseBenefit | Deferred State and Local Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | DeferredTaxAssetsGoodwillAndIntangibleAssets | Deferred Tax Assets, Goodwill and Intangible Assets | USD | 78,378 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 130.97M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredTaxAssetsInProcessResearchAndDevelopment | Deferred Tax Assets, in Process Research and Development | USD | 1.13M | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-05 | 0001193125-25-266989 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 75,365 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal | Deferred Tax Assets, Operating Loss Carryforwards, State and Local | USD | 89.13M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 98,731 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredTaxAssetsPropertyPlantAndEquipment | Deferred Tax Assets, Property, Plant and Equipment | USD | 10,173 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-08 | 0001564590-19-006997 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsResearch | Deferred Tax Assets, Tax Credit Carryforwards, Research | USD | 18.19M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 3.63M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | USD | 2.89M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-28 | 0000950170-25-030102 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 130.89M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs | USD | 2.21M | 2024-12-31 | 2024 | FY | 10-K | 2025-02-28 | 0000950170-25-030102 | |
| us-gaap | DeferredTaxLiabilitiesLeasingArrangements | Deferred Tax Liabilities, Leasing Arrangements | USD | 75,365 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | DeferredTaxLiabilitiesPropertyPlantAndEquipment | Deferred Tax Liabilities, Property, Plant and Equipment | USD | 97 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 | |
| us-gaap | DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities | Deferred Tax Liabilities, Unrealized Gains on Trading Securities | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | Depreciation | Depreciation | USD | 292,017 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | DepreciationAmortizationAndAccretionNet | Depreciation, Amortization and Accretion, Net | USD | 202,909 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-10-28 | 0000950170-21-002456 |
| us-gaap | DerivativeGainLossOnDerivativeNet | Derivative, Gain (Loss) on Derivative, Net | USD | -2.33M | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 |
| us-gaap | DerivativeLiabilitiesNoncurrent | Derivative Liability, Noncurrent | USD | 253,247 | 2013-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 | |
| us-gaap | DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage | Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) | USD | 40.92M | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-06-11 | 0001193125-14-233411 | |
| us-gaap | DividendsPreferredStockCash | Dividends, Preferred Stock, Cash | USD | 15.70M | 2012-01-01 | 2012-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -0.21 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -0.29 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-05 | 0000950170-22-007890 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -0.21 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | 0.214 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent | pure | -0.398 | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-08 | 0001564590-19-006997 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent | pure | 0.043 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | 0.011 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | 0.002 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent | pure | -0.021 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsOther | Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent | pure | 0 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | 0.025 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | EmployeeBenefitsAndShareBasedCompensation | Employee Benefits and Share-based Compensation | USD | 300,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 839,516 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | USD | 7.50M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0000950170-22-004111 | |
| us-gaap | FairValueAdjustmentOfWarrants | Fair Value Adjustment of Warrants | USD | -2.33M | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 5.80M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax | Impact of Restatement on Opening Retained Earnings, Net of Tax (Deprecated 2020-01-31) | USD | 0 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010493 | |
| us-gaap | IncomeLossAttributableToParent | Income (Loss) Attributable to Parent, before Tax | USD | 33.85M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | 33.85M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -57.78M | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0000950170-22-004111 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | IncomeTaxesPaid | Income Taxes Paid | USD | 0 | 2017-01-01 | 2017-09-30 | 2017 | Q3 | 10-Q | 2017-11-09 | 0001193125-17-338853 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 7.25M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | 7.11M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | 380,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | IncomeTaxReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | USD | 51,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 837,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | -14,018 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | -3.05M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities | USD | 4.51M | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-10-28 | 0000950170-21-002456 |
| us-gaap | IncreaseDecreaseInDeferredCharges | Increase (Decrease) in Deferred Charges | USD | 21,998 | 2015-01-01 | 2015-09-30 | 2015 | Q3 | 10-Q | 2015-11-13 | 0001193125-15-376648 |
| us-gaap | IncreaseDecreaseInDeferredLiabilities | Increase (Decrease) in Deferred Liabilities | USD | 50,000 | 2013-01-01 | 2013-09-30 | 2014 | Q3 | 10-Q | 2014-11-12 | 0001193125-14-408602 |
| us-gaap | IncreaseDecreaseInInterestPayableNet | Increase (Decrease) in Interest Payable, Net | USD | -2,125 | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 |
| us-gaap | IncreaseDecreaseInNotesPayableRelatedParties | Increase (Decrease) in Notes Payable, Related Parties | USD | -2,125 | 2014-01-01 | 2014-06-30 | 2015 | Q2 | 10-Q | 2015-08-14 | 0001193125-15-290681 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 201,616 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | IncrementalCommonSharesAttributableToCallOptionsAndWarrants | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants | shares | 32,455 | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 |
| us-gaap | IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements | Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements | shares | 107,416 | 2013-01-01 | 2013-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 |
| us-gaap | IncrementalCommonSharesAttributableToShareBasedPaymentArrangements | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements | shares | 4,851 | 2014-01-01 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-06-11 | 0001193125-14-233411 |
| us-gaap | InterestExpense | Interest Expense | USD | 976,128 | 2024-01-01 | 2024-06-30 | 2024 | Q2 | 10-Q | 2024-08-01 | 0000950170-24-089238 |
| us-gaap | InterestExpenseNonoperating | InterestExpenseNonoperating | USD | 469,140 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | InterestPaid | Interest Paid, Including Capitalized Interest, Operating and Investing Activities | USD | 22,682 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-15 | 0001193125-18-164070 |
| us-gaap | InterestPaidNet | Interest Paid, Excluding Capitalized Interest, Operating Activities | USD | 559,625 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | InterestPayableCurrent | Interest Payable, Current | USD | 1,425 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 | |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 1.34M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | LeaseAndRentalExpense | Operating Leases, Rent Expense | USD | 238,532 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-08 | 0001564590-19-006997 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 513,108 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 98,949 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 115,911 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 151,158 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 147,090 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 57,275 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-07 | 0001564590-19-041846 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 54,410 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | Liabilities | Liabilities | USD | 8.16M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 43.38M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 7.88M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | LiabilitiesFairValueDisclosure | Financial and Nonfinancial Liabilities, Fair Value Disclosure | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | LineOfCredit | Long-term Line of Credit | USD | 1.40M | 2013-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 | |
| us-gaap | LineOfCreditFacilityAmountOutstanding | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) | USD | 500,000 | 2012-04-12 | 2014 | Q2 | 10-Q | 2014-08-07 | 0001193125-14-300661 | |
| us-gaap | LineOfCreditFacilityAnnualPrincipalPayment | Line of Credit Facility, Annual Principal Payment | USD | 58,160 | 2016-01-01 | 2016-09-30 | 2016 | Q3 | 10-Q | 2016-11-14 | 0001193125-16-767770 |
| us-gaap | LineOfCreditFacilityCommitmentFeeAmount | Line of Credit Facility, Commitment Fee Amount | USD | 375,000 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001564590-20-051290 |
| us-gaap | LineOfCreditFacilityCommitmentFeePercentage | Line of Credit Facility, Commitment Fee Percentage | pure | 0.07 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001564590-20-051290 |
| us-gaap | LineOfCreditFacilityCurrentBorrowingCapacity | Line of Credit Facility, Current Borrowing Capacity | USD | 1.00M | 2013-11-30 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 | |
| us-gaap | LineOfCreditFacilityInterestRateAtPeriodEnd | Line of Credit Facility, Interest Rate at Period End | pure | 0.129 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001564590-20-051290 | |
| us-gaap | LineOfCreditFacilityInterestRateDuringPeriod | Line of Credit Facility, Interest Rate During Period | pure | 0.091 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001564590-20-051290 |
| us-gaap | LineOfCreditFacilityMaximumBorrowingCapacity | Line of Credit Facility, Maximum Borrowing Capacity | USD | 500,000 | 2012-12-31 | 2014 | Q3 | 10-Q | 2014-11-12 | 0001193125-14-408602 | |
| us-gaap | LineOfCreditFacilityPeriodicPaymentPrincipal | Line of Credit Facility, Periodic Payment, Principal | USD | 20,833 | 2012-01-01 | 2012-12-31 | 2014 | Q3 | 10-Q | 2014-11-12 | 0001193125-14-408602 |
| us-gaap | LinesOfCreditCurrent | Line of Credit, Current | USD | 279,957 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-07 | 0000950170-24-123248 | |
| us-gaap | LongTermDebt | Long-term Debt | USD | 15.30M | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-07 | 0001341235-26-000006 | |
| us-gaap | LongTermDebtCurrent | Long-term Debt, Current Maturities | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths | Long-Term Debt, Maturity, Year One | USD | 15.30M | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-07 | 0001341235-26-000006 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive | Long-Term Debt, Maturity, Year Five | USD | 6.45M | 2018-12-31 | 2019 | Q3 | 10-Q | 2019-11-07 | 0001564590-19-041846 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour | Long-Term Debt, Maturity, Year Four | USD | 6.45M | 2019-12-31 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001564590-20-051290 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree | Long-Term Debt, Maturity, Year Three | USD | 6.45M | 2020-12-31 | 2020 | FY | 10-K | 2021-03-11 | 0001564590-21-012501 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo | Long-Term Debt, Maturity, Year Two | USD | 15.30M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear | Long-Term Debt, Maturity, Remainder of Fiscal Year | USD | 292,500 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-07 | 0000950170-24-123248 | |
| us-gaap | LongTermDebtNoncurrent | Long-term Debt, Excluding Current Maturities | USD | 0 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-07 | 0001341235-26-000006 | |
| us-gaap | LongTermLoansPayable | Loans Payable, Noncurrent | USD | 15.00M | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-07 | 0001341235-26-000006 | |
| us-gaap | MarketableSecurities | Marketable Securities | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | MarketableSecuritiesCurrent | Marketable Securities, Current | USD | 46.62M | 2024-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | MarketableSecuritiesUnrealizedGainLoss | Marketable Securities, Unrealized Gain (Loss) | USD | -100,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | MoneyMarketFundsAtCarryingValue | Money Market Funds, at Carrying Value | USD | 8.64M | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-05 | 0000950170-22-015115 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | -15.22M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | NetCashProvidedByUsedInFinancingActivitiesContinuingOperations | Net Cash Provided by (Used in) Financing Activities, Continuing Operations | USD | 4.09M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-15 | 0001193125-18-164070 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | -23,097 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | NetCashProvidedByUsedInInvestingActivitiesContinuingOperations | Net Cash Provided by (Used in) Investing Activities, Continuing Operations | USD | 4.80M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-15 | 0001193125-18-164070 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -13.82M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | Net Cash Provided by (Used in) Operating Activities, Continuing Operations | USD | -7.95M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-15 | 0001193125-18-164070 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -12.67M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersBasic | Net Income (Loss) Available to Common Stockholders, Basic | USD | -4.97M | 2016-01-01 | 2016-03-31 | 2016 | Q1 | 10-Q | 2016-05-09 | 0001193125-16-582737 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersDiluted | Net Income (Loss) Available to Common Stockholders, Diluted | USD | -4.97M | 2016-01-01 | 2016-03-31 | 2016 | Q1 | 10-Q | 2016-05-09 | 0001193125-16-582737 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 867,842 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -13.53M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | OperatingLeaseExpense | Operating Lease, Expense | USD | 300,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 458,698 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 178,577 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 280,121 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 445,121 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 465,991 | 2018-12-31 | 2019 | Q2 | 10-Q | 2019-08-09 | 0001564590-19-031031 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 228,320 | 2018-12-31 | 2019 | Q2 | 10-Q | 2019-08-09 | 0001564590-19-031031 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 0 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-29 | 0001193125-18-102077 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 0 | 2018-12-31 | 2019 | Q2 | 10-Q | 2019-08-09 | 0001564590-19-031031 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 237,671 | 2018-12-31 | 2019 | Q2 | 10-Q | 2019-08-09 | 0001564590-19-031031 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | USD | 17,000 | 2014-09-30 | 2014 | Q3 | 10-Q | 2014-11-12 | 0001193125-14-408602 | |
| us-gaap | OperatingLeasesRentExpenseNet | Operating Leases, Rent Expense, Net | USD | 5,604 | 2014-01-01 | 2014-12-31 | 2016 | FY | 10-K | 2017-03-30 | 0001193125-17-104228 |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.088 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 48,657 | 2015-12-31 | 2016 | Q3 | 10-Q | 2016-11-14 | 0001193125-16-767770 | |
| us-gaap | OtherAccruedLiabilitiesCurrentAndNoncurrent | Other Accrued Liabilities | USD | 502,232 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | OtherAssetsCurrent | Other Assets, Current | USD | 755,545 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-14 | 0000950170-25-071602 | |
| us-gaap | OtherAssetsMiscellaneousCurrent | Other Assets, Miscellaneous, Current | USD | 459,593 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | OtherComprehensiveIncomeLossNetOfTax | Other Comprehensive Income (Loss), Net of Tax | USD | -37,442 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | OtherNonoperatingExpense | Other Nonoperating Expense | USD | 1,987 | 2013-01-01 | 2013-09-30 | 2014 | Q3 | 10-Q | 2014-11-12 | 0001193125-14-408602 |
| us-gaap | OtherNonoperatingIncome | Other Nonoperating Income | USD | 250,756 | 2004-08-13 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-06-11 | 0001193125-14-233411 |
| us-gaap | PaymentsOfDebtIssuanceCosts | Payments of Debt Issuance Costs | USD | 300,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | PaymentsRelatedToTaxWithholdingForShareBasedCompensation | Payment, Tax Withholding, Share-based Payment Arrangement | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-28 | 0000950170-25-030102 |
| us-gaap | PaymentsToAcquireAvailableForSaleSecurities | Payments to Acquire Available-for-sale Securities | USD | 0 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-10-28 | 0000950170-21-002456 |
| us-gaap | PaymentsToAcquireMarketableSecurities | Payments to Acquire Marketable Securities | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-07 | 0000950170-24-027933 |
| us-gaap | PreferredStockAccretionOfRedemptionDiscount | Preferred Stock, Accretion of Redemption Discount | USD | 333,082 | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 |
| us-gaap | PreferredStockDividendsAndOtherAdjustments | Preferred Stock Dividends and Other Adjustments | USD | 15.66M | 2004-08-13 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-06-11 | 0001193125-14-233411 |
| us-gaap | PreferredStockDividendsIncomeStatementImpact | Preferred Stock Dividends, Income Statement Impact | USD | 4.05M | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 15.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 1.94M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | PrepaidInsurance | Prepaid Insurance | USD | 867,907 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 10.00M | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-30 | 0001193125-17-104228 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 0 | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-05 | 0001193125-25-266989 |
| us-gaap | ProceedsFromIssuanceOfLongTermDebt | Proceeds from Issuance of Long-term Debt | USD | 14.45M | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-11 | 0001564590-21-012501 |
| us-gaap | ProceedsFromIssuanceOfPrivatePlacement | Proceeds from Issuance of Private Placement | USD | 1.90M | 2015-01-21 | 2018 | Q3 | 10-Q | 2018-11-14 | 0001193125-18-326837 | |
| us-gaap | ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock | Proceeds from Issuance of Redeemable Convertible Preferred Stock | USD | 2.75M | 2013-01-01 | 2013-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 |
| us-gaap | ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised | USD | 9,692 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised | USD | 194,849 | 2019-01-01 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-07 | 0001564590-19-041846 |
| us-gaap | ProceedsFromLinesOfCredit | Proceeds from Lines of Credit | USD | 1.40M | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 |
| us-gaap | ProceedsFromNotesPayable | Proceeds from Notes Payable | USD | 170,000 | 2013-01-01 | 2013-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 |
| us-gaap | ProceedsFromRepurchaseOfEquity | Proceeds from (Repurchase of) Equity | USD | 19.50M | 2015-05-22 | 2016 | FY | 10-K | 2017-03-30 | 0001193125-17-104228 | |
| us-gaap | ProceedsFromSaleAndMaturityOfMarketableSecurities | Proceeds from Sale and Maturity of Marketable Securities | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 71,140 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -12.67M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 17,991 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | RepaymentsOfLinesOfCredit | Repayments of Lines of Credit | USD | 1.40M | 2018-01-01 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010493 |
| us-gaap | RepaymentsOfLongTermDebtAndCapitalSecurities | Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security | USD | 15.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | RepaymentsOfNotesPayable | Repayments of Notes Payable | USD | 41,667 | 2013-01-01 | 2013-06-30 | 2014 | Q2 | 10-Q | 2014-08-07 | 0001193125-14-300661 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 7.73M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ResearchAndDevelopmentInProcess | Research and Development in Process | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0000950170-22-004111 |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -496.62M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 300,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | SaleOfStockNumberOfSharesIssuedInTransaction | Sale of Stock, Number of Shares Issued in Transaction | shares | 211,528 | 2015-01-21 | 2018 | Q3 | 10-Q | 2018-11-14 | 0001193125-18-326837 | |
| us-gaap | SaleOfStockPricePerShare | Sale of Stock, Price Per Share | USD/shares | 9.33 | 2015-01-21 | 2018 | Q3 | 10-Q | 2018-11-14 | 0001193125-18-326837 | |
| us-gaap | SecuritiesForReverseRepurchaseAgreements | Securities for Reverse Repurchase Agreements | USD | 11.00M | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-14 | 0001193125-18-326837 | |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 1.77M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | shares | 604,009 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-07 | 0000950170-24-123248 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | USD/shares | 5.41 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-07 | 0000950170-24-123248 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 0.89 | 2016-01-01 | 2016-12-31 | 2016 | FY | 10-K | 2017-03-30 | 0001193125-17-104228 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | shares | 871,571 | 2015-01-01 | 2015-03-31 | 2015 | Q1 | 10-Q | 2015-05-14 | 0001193125-15-187962 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 5.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 5.4 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 12,997 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period | shares | 1.50M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 875,824 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 2.70M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 3.76 | 2017-01-01 | 2017-12-31 | 2017 | FY | 10-K | 2018-03-29 | 0001193125-18-102077 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 8.89M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 4.39 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | USD | 1.40M | 2014-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | USD/shares | 1.57 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | USD | 1.80M | 2014-01-01 | 2014-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | shares | 165,162 | 2019-01-01 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-09 | 0001564590-19-031031 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent | Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | pure | 1 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 3.56 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | USD/shares | 5.97 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 4.45 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 1.77 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | SharePrice | Share Price | USD/shares | 1.23 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 35.22M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 | |
| us-gaap | StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | USD | 123.01M | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-03 | 0000950170-23-058829 | |
| us-gaap | StockIssuedDuringPeriodSharesNewIssues | Stock Issued During Period, Shares, New Issues | shares | 444,000 | 2018-04-01 | 2018-05-15 | 2018 | Q1 | 10-Q | 2018-05-15 | 0001193125-18-164070 |
| us-gaap | StockIssuedDuringPeriodSharesRestrictedStockAwardGross | Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 20,009 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | Stock Issued During Period, Value, Conversion of Convertible Securities | USD | 170,000 | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockPurchasePlan | Stock Issued During Period, Value, Employee Stock Purchase Plan | USD | 9,692 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 23,324 | 2022-01-01 | 2022-03-31 | 2023 | Q1 | 10-Q | 2023-05-04 | 0000950170-23-017827 |
| us-gaap | StockIssuedDuringPeriodValueRestrictedStockAwardGross | Stock Issued During Period, Value, Restricted Stock Award, Gross | USD | 0 | 2023-01-01 | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-05-04 | 0000950170-23-017827 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 71,140 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense | Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense) | USD | 400,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | StockOptionPlanExpense | Stock or Unit Option Plan Expense | USD | 340,000 | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 |
| us-gaap | TaxCreditCarryforwardAmount | Tax Credit Carryforward, Amount | USD | 2.80M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 | |
| us-gaap | TemporaryEquityAccretionToRedemptionValueAdjustment | Temporary Equity, Accretion to Redemption Value, Adjustment | USD | 333,082 | 2014-01-01 | 2014-12-31 | 2015 | FY | 10-K | 2016-03-30 | 0001193125-16-523952 |
| us-gaap | TemporaryEquityCarryingAmountAttributableToParent | Temporary Equity, Carrying Amount, Attributable to Parent | USD | 38.32M | 2013-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 | |
| us-gaap | UnamortizedDebtIssuanceExpense | Unamortized Debt Issuance Expense | USD | 0 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-07 | 0001341235-26-000006 | |
| us-gaap | UndistributedEarningsAllocatedToParticipatingSecurities | Undistributed Earnings Allocated to Participating Securities (Deprecated 2014-01-31) | USD | 11.35M | 2004-08-13 | 2014-03-31 | 2014 | Q1 | 10-Q | 2014-06-11 | 0001193125-14-233411 |
| us-gaap | UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic | Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | USD | 223,442 | 2014-01-01 | 2014-03-31 | 2015 | Q1 | 10-Q | 2015-05-14 | 0001193125-15-187962 |
| us-gaap | UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense | Unrecognized Tax Benefits, Interest on Income Taxes Expense | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-28 | 0000950170-25-030102 |
| us-gaap | USGovernmentSecuritiesAtCarryingValue | US Government Securities, at Carrying Value | USD | 28.93M | 2019-12-31 | 2020 | FY | 10-K | 2021-03-11 | 0001564590-21-012501 | |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | 9.40M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-27 | 0001193125-26-083012 |
| us-gaap | WarrantsAndRightsOutstanding | Warrants and Rights Outstanding | USD | 178,000 | 2013-11-30 | 2017 | FY | 10-K | 2018-03-29 | 0001193125-18-102077 | |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 60.33M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 58.30M | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-05 | 0000950170-22-007890 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 60.33M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |
| us-gaap | WeightedAverageNumberOfSharesTreasuryStock | Weighted Average Number of Shares, Treasury Stock | shares | 429,663 | 2013-01-01 | 2013-12-31 | 2014 | FY | 10-K | 2015-03-23 | 0001193125-15-101703 |
| us-gaap | WriteOffOfDeferredDebtIssuanceCost | Write off of Deferred Debt Issuance Cost | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449742 |